ArticleJournal of neuroinflammation2025
A systematic scoring system to optimise the testing of neurotherapeutics in models of perinatal brain injury, with an applied case study of human umbilical-cord MSC.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
The preclinical stages of therapeutic agent development cost hundreds of millions of dollars, stymying innovation and slowing the development of products to improve human health. There is a striking unmet need for therapies that protect or repair the brain damage associated with preterm birth, i.e., delivery before 37 weeks of gestation. Of the more than 15 million babies born preterm every year, up to 60% will go on to develop a neurological disorder, with the earliest-born infants the most impacted. We have limited options with limited efficacy for preventing or treating these changes. Combining accurate knowledge of pathophysiology with high-throughput sequencing and computational biology approaches is a logical step towards an optimised screening pipeline. In this study, we conducted comprehensive testing of dose, timing, and route of administration, integrating multimodal data from preclinical models of brain injury common in preterm-born infants to validate the most effective therapeutic option for the cord-derived mesenchymal stem cell product (HuMSC). In this study, HuMSC serves as a working example, but the scoring system is therapy-agnostic. We developed a scoring protocol based on microglia transcriptome analyses and myelin protein expression to evaluate the efficacy of the HuMSC product in a rat model of inflammation-associated preterm infant brain injury. We identified the superiority of treatment delivered in the tertiary phase of injury over treatments in the acute or subacute stages, as well as the superiority of intranasal over intravenous delivery of HuMSCs. The optimal time, dose, and route of administration options for HuMSC were confirmed in a second model relevant to preterm infants, but with a different pathophysiology, namely germinal matrix haemorrhage. In conclusion, we have established a scoring protocol that expedites the collection of comprehensive dose, time and route of administration data critical for establishing large animal and clinical trials with the greatest chance of success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.